Literature DB >> 21710362

Association study between BDNF C-281A polymorphism and paranoid schizophrenia in Polish population.

Renata Suchanek1, Aleksander Owczarek, Jan Kowalski.   

Abstract

Brain-derived neurotrophic factor (BDNF) is one of the candidate genes for schizophrenia. Polymorphism C-281A (rs28383487) in BDNF gene leads to the reduction of promoter activity in the hippocampal neurons in vitro. To our knowledge, this is the first study to examine the influence of alleles and genotypes of BDNF C-281A polymorphism on development, as well as the clinical course (age of onset, suicidal behaviour and psychopathology) of paranoid schizophrenia. The psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS) as subscale scores and also single-item scores. We have also performed the haplotype analysis with val66met BDNF polymorphism, which is known to be involved in the pathogenesis of schizophrenia. We have not found significant differences in the distribution of genotypes and alleles between schizophrenic patients and controls in both the overall analysis, as well as sex stratified. Also, we have not shown statistically significant differences between genotype groups and PANSS scale. However, an association between C-281A polymorphism and time of the first episode of paranoid schizophrenia was revealed. Genotype C/A had been connected with later age of onset of paranoid schizophrenia in men but not in women (p < 0.01). The C-281A and val66met polymorphisms have been in a strong linkage disequilibrium (D' = 0.9875; p < 0.05). The haplotype analysis has shown a tendency to a significantly lower frequency of the Met-C haplotype in the schizophrenia group compared to the controls.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21710362     DOI: 10.1007/s12031-011-9582-7

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  29 in total

Review 1.  Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression.

Authors:  Hiroshi Kunugi; Hiroaki Hori; Naoki Adachi; Tadahiro Numakawa
Journal:  Psychiatry Clin Neurosci       Date:  2010-10       Impact factor: 5.188

Review 2.  Neurotrophin signalling in health and disease.

Authors:  Moses V Chao; Rithwick Rajagopal; Francis S Lee
Journal:  Clin Sci (Lond)       Date:  2006-02       Impact factor: 6.124

3.  BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects.

Authors:  Xueying Jiang; Ke Xu; Joelle Hoberman; Feng Tian; Aimee J Marko; Juwaria F Waheed; Claudia R Harris; Ann M Marini; Mary-Anne Enoch; Robert H Lipsky
Journal:  Neuropsychopharmacology       Date:  2005-07       Impact factor: 7.853

4.  Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients.

Authors:  Tiao-Lai Huang; Chien-Te Lee
Journal:  J Psychiatr Res       Date:  2005-12-28       Impact factor: 4.791

5.  Reduced brain-derived neurotrophic factor is associated with a loss of serotonergic innervation in the hippocampus of aging mice.

Authors:  B A Luellen; L E Bianco; L M Schneider; A M Andrews
Journal:  Genes Brain Behav       Date:  2006-12-06       Impact factor: 3.449

6.  BDNF Val66Met polymorphism is associated with HPA axis reactivity to psychological stress characterized by genotype and gender interactions.

Authors:  Idan Shalev; Elad Lerer; Salomon Israel; Florina Uzefovsky; Inga Gritsenko; David Mankuta; Richard P Ebstein; Marsha Kaitz
Journal:  Psychoneuroendocrinology       Date:  2008-11-05       Impact factor: 4.905

7.  Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes.

Authors:  Da Chun Chen; Jing Wang; Bo Wang; Sheng Chang Yang; Chong Xi Zhang; You Lan Zheng; Yan Li Li; Ning Wang; Ke Bing Yang; Mei Hong Xiu; Thomas R Kosten; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2009-09-29       Impact factor: 4.530

8.  Brain-derived neurotrophic factor Val66Met polymorphism: association with psychopathological symptoms of schizophrenia?

Authors:  Hsin-An Chang; Ru-Band Lu; Mee-Jen Shy; Chuan-Chia Chang; Meei-Shyuan Lee; San-Yuan Huang
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2009       Impact factor: 2.198

9.  Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia.

Authors:  C S Weickert; T M Hyde; B K Lipska; M M Herman; D R Weinberger; J E Kleinman
Journal:  Mol Psychiatry       Date:  2003-06       Impact factor: 15.992

Review 10.  Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes.

Authors:  Heike Tost; Tajvar Alam; Andreas Meyer-Lindenberg
Journal:  Neurosci Biobehav Rev       Date:  2009-06-24       Impact factor: 8.989

View more
  3 in total

1.  Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction.

Authors:  M Ayalew; H Le-Niculescu; D F Levey; N Jain; B Changala; S D Patel; E Winiger; A Breier; A Shekhar; R Amdur; D Koller; J I Nurnberger; A Corvin; M Geyer; M T Tsuang; D Salomon; N J Schork; A H Fanous; M C O'Donovan; A B Niculescu
Journal:  Mol Psychiatry       Date:  2012-05-15       Impact factor: 15.992

2.  BDNF Val66Met variant and smoking in a Chinese population.

Authors:  Xiang Yang Zhang; Da Chun Chen; Mei Hong Xiu; Xingguang Luo; Lingjun Zuo; Colin N Haile; Therese A Kosten; Thomas R Kosten
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

3.  Schizophrenia susceptibility and NMDA-receptor mediated signalling: an association study involving 32 tagSNPs of DAO, DAOA, PPP3CC, and DTNBP1 genes.

Authors:  Emilio Sacchetti; Catia Scassellati; Alessandra Minelli; Paolo Valsecchi; Cristian Bonvicini; Patrizio Pasqualetti; Alessandro Galluzzo; Rosaria Pioli; Massimo Gennarelli
Journal:  BMC Med Genet       Date:  2013-03-09       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.